Unknown

Dataset Information

0

Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.

ABSTRACT:

SUBMITTER: Fang W 

PROVIDER: S-EPMC7240844 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.

Fang Wenfeng W   Ma Yuxiang Y   Yin Jiani C JC   Zhou Huaqiang H   Wang Fufeng F   Bao Hua H   Wang Ao A   Wu Xue X   Hong Shaodong S   Yang Yunpeng Y   Huang Yan Y   Zhao Hongyun H   Shao Yang W YW   Zhang Li L  

Clinical and translational medicine 20200101 1

Similar Datasets

Unknown Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA.
| S-EPMC7327335 | biostudies-literature
Unknown Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma.
| S-EPMC6885440 | biostudies-literature
Unknown Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
| S-EPMC6549688 | biostudies-literature
Unknown Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.
| S-EPMC12328289 | biostudies-literature
Unknown NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
| S-EPMC7288635 | biostudies-literature
Unknown Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers.
| S-EPMC10248461 | biostudies-literature
Unknown Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
| S-EPMC5944039 | biostudies-literature
Unknown Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.
| S-EPMC9960420 | biostudies-literature
Unknown Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.
| S-EPMC9714418 | biostudies-literature
Unknown Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
| S-EPMC7366360 | biostudies-literature